A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world
Yin Wan,1 Shawn X Sun,2 Shelby Corman,1 Xingyue Huang,2 Xin Gao,1 Andrew F Shorr3 1Health Economics and Modeling, Outcomes Research, Pharmerit International, Bethesda, MD, USA; 2Health Economics and Outcomes Research, Forest Laboratories, LLC, an affiliate of Actavis, Inc., Jersey City, NJ, USA; 3P...
Main Authors: | Wan Y, Sun SX, Corman S, Huang X, Gao X, Shorr AF |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-10-01
|
Series: | International Journal of COPD |
Online Access: | https://www.dovepress.com/a-longitudinal-retrospective-cohort-study-on-the-impact-of-roflumilast-peer-reviewed-article-COPD |
Similar Items
-
Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease
by: Fu AZ, et al.
Published: (2015-05-01) -
Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations
by: Imane Achir Alispahic, et al.
Published: (2020-05-01) -
Roflumilast: A Review of Chronic Obstructive Pulmonary Disease (COPD) Treatment
by: Ita Octafia, et al.
Published: (2021-01-01) -
Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
by: Kim KH, et al.
Published: (2017-12-01) -
Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population
by: Moll K, et al.
Published: (2015-03-01)